Peanut Allergy Pipeline Insight
DelveInsight’s, “Peanut Allergy – Pipeline Insights, 2021,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Peanut Allergy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Peanut Allergy Understanding
Peanut Allergy: Overview
A peanut allergy is a reaction that occurs when body mistakenly identifies peanuts as harmful substances. When you eat peanuts or food containing peanuts, your immune system —the body's natural defense system that fights infections and diseases—overreacts and can cause a serious, even life-threatening response.
The most severe allergic reaction to peanuts is anaphylaxis — a life-threatening whole-body response to an allergen. Symptoms may include impaired breathing, swelling in the throat, a sudden drop in blood pressure, pale skin or blue lips, fainting and dizziness. Anaphylaxis should be treated immediately with epinephrine (adrenaline), typically administered in an auto-injector.
Symptoms of a peanut allergy may include:
- Stomach cramps
- Shortness of breath, difficulty breathing
- Repetitive cough
- Tightness in throat, hoarse voice
- Weak pulse
- Pale or blue coloring of the skin
- Swelling, can affect the tongue and/or lips
To diagnose a peanut allergy, the doctor will start with a medical history and a physical exam. he will ask about any family food allergies, especially siblings with peanut allergies. He or she will ask detailed questions about symptoms, how soon symptoms began after the patient ate the food, and if any over-the-counter allergy medicines like an antihistamine were helpful. The doctor will ask if other people also got sick, how the food was prepared, and what other foods were eaten.
It's important to find out whether the patient have a food allergy or food intolerance. He or she may ask to keep a record of all the foods patient’s eat and any reactions to the foods. The doctor will also consider if reaction could have been caused by things like allergies to medicines or insect stings, food poisoning, irritants in foods, and exposure to skin irritants.
For a mild reaction, to reduce the symptoms, the patient may only need to take an antihistamine, such as a nondrowsy one like loratadine (Claritin) or one that might make the patient sleepy like diphenhydramine (Benadryl). Mild symptoms include sneezing or an itchy or runny nose; an itchy mouth; a few hives or mild itching; and mild nausea or stomach discomfort. If the patient have had a severe reaction previously, the doctor has probably prescribed a medicine called epinephrine.
Peanut Allergy Emerging Drugs Chapters
This segment of the Peanut Allergy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Peanut Allergy Emerging Drugs
- Viaskin Peanut: DBV Technologies
DBV is developing the Viaskin technology platform, which delivers biologically active compounds, including allergens, via intact skin. Viaskin is an electrostatic patch, based on Epicutaneous Immunotherapy, or EPIT®, which administers an allergen directly onto the superficial layers of the skin to activate the immune system by specifically targeting antigen-presenting cells without allowing passage of the antigen into the bloodstream. Viaskin® Peanut is currently being investigated in clinical trials for treatment of peanut allergy.
- Dupilumab: Regeneron Pharmaceuticals/Sanofi
Dupilumab is a IL-4R Antibody that is being developed by Regeneron Pharmaceuticals in collaboration with Sanofi for the treatment of Peanut Allergy. It is currently in phase II stage of development.
Etokimab is a first-in-Class anti-IL-33 antibody that is being developed AnaptysBio for the treatment of Peanut allergy. Efficacy and safety has previously been reported in adult moderate-to-severe atopic dermatitis and severe adult peanut allergy patients. It is currently in phase II stage of development.
ASP0892 is a next generation vaccine that is being developed by Astellas pharma for the treatment of Peanut allergy. It is currently in phase I stage of development.
- CNP 201: Cour Pharmaceutical Developmentz
CNP 201 is being developed by Cour Pharmaceutical Development for the treatment of Peanut allergy. It is currently in preclinical stage of development
Further product details are provided in the report……..
Peanut Allergy: Therapeutic Assessment
This segment of the report provides insights about the different Peanut Allergy drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Peanut Allergy
There are approx. 20+ key companies which are developing the therapies for Peanut Allergy. The companies which have their Peanut Allergy drug candidates in the most advanced stage, i.e. phase III include DBV Technologies and others
DelveInsight’s report covers around 20+ products under different phases of clinical development like
- Late-stage products (Phase II and Phase II/III)
- Mid-stage products (Phase II and Phase II/III)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Peanut Allergy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Gene therapies
- Small molecule
- Monoclonal antibodies
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Peanut Allergy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Peanut Allergy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Peanut Allergy drugs.
- The companies and academics are working to assess challenges and seek opportunities that could influence Peanut Allergy R&D. The therapies under development are focused on novel approaches to treat/improve Peanut Allergy.
- In October 2019, DBV Technologies announced that the US Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for its investigational Viaskin Peanut immunotherapy for the treatment of peanut-allergic children ages 4 to 11 years.
- In April 2015 DBV Technologies stated that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Viaskin Peanut for children.
- In 2012, Viaskin Peanut received Fast Track Designation from the FDA in 2012.
Peanut Allergy Report Insights
- Peanut Allergy Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Peanut Allergy Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Peanut Allergy drugs?
- How many Peanut Allergy drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Peanut Allergy?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Peanut Allergy therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Peanut Allergy and their status?
- What are the key designations that have been granted to the emerging drugs?
- Regeneron Pharmaceuticals
- Aimmune Therapeutics
- DBV Technologies
- HAL Allergy
- Astellas Pharma
- Mast Cell Pharmaceuticals
- Vedanta Biosciences, Inc.
- Cour Pharmaceutical Development
- Viaskin Peanut
- CNP 201